Amgen Inc.
Income Statement
| Line Item | FY2009 | FY2008 | FY2007 |
|---|---|---|---|
| Revenue | $14.64B | $15.00B | $14.77B |
| Repatha | — | — | — |
| EVENITY | — | — | — |
| Prolia | — | — | — |
| TEPEZZA | — | — | — |
| KRYSTEXXA | — | — | — |
| UPLIZNA | — | — | — |
| TAVNEOS | — | — | — |
| Ultra-Rare products | — | — | — |
| TEZSPIRE | — | — | — |
| Otezla | — | — | — |
| Enbrel | — | — | — |
| AMJEVITA/AMGEVITA | — | — | — |
| BLINCYTO | — | — | — |
| Vectibix | — | — | — |
| KYPROLIS | — | — | — |
| LUMAKRAS/LUMYKRAS | — | — | — |
| XGEVA | — | — | — |
| Nplate | — | — | — |
| IMDELLTRA | — | — | — |
| MVASI | — | — | — |
| EPOGEN | — | — | — |
| Aranesp | — | — | — |
| Parsabiv | — | — | — |
| Neulasta | — | — | — |
| NEUPOGEN | — | — | — |
| Sensipar/Mimpara | — | — | — |
| Other products | — | — | — |
| Other revenues | — | — | — |
| Cost of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin | — | — | — |
| Operating Expenses | |||
| Research & Development | — | — | — |
| SG&A Expense | $3.82B | $3.79B | $3.36B |
| Operating Income | $5.51B | $5.21B | $3.98B |
| Operating Margin | 37.6% | 34.8% | 26.9% |
| Interest Expense | $578.0M | $551.0M | $496.0M |
| Pretax Income | $5.20B | $5.02B | $3.79B |
| Income Tax Expense | $599.0M | $963.0M | $715.0M |
| Net Income | $4.61B | $4.05B | $3.08B |
| Net Margin | 31.5% | 27.0% | 20.8% |
| EPS (Basic) | $4.53 | $3.79 | $2.76 |
| EPS (Diluted) | $4.51 | $3.77 | $2.74 |
| Shares Outstanding (Basic) | 1.02B | 1.07B | 1.12B |
| Shares Outstanding (Diluted) | 1.02B | 1.08B | 1.12B |
| Dividends Per Share | — | — | — |